Abstract

To examine the rate and time to relapse for remitters and responders to ketamine in treatment-resistant depression (TRD).Subjects with TRD were randomized to a single infusion of one of several doses of intravenous ketamine, or midazolam. Using Kaplan-Meier survival function, the current report examines the rate and time to relapse, defined as MADRS = 22, over a period of 30 days, in subjects who achieved remission (MADRS = 10) or response (= 50% reduction in MADRS) on day three post-infusion of intravenous ketamine 0.1, 0.5, or 1.0?mg/kg.Of the 60 randomized participants who received a single ketamine (0.1, 0.5, or 1.0?mg/kg) infusion, 19 (34%) met criteria for remission and 27 (48%) for response, on day 3 post-infusion. A numerical dose-response relationship was observed, with remitters/responders on ketamine 1.0?mg/kg having the lowest relapse rate, followed by ketamine 0.5?mg/kg and 0.1?mg/kg, respectively (% of remitters who relapsed by day 14: 38% with 1.0?mg/kg, 50% with 0.5?mg/kg, 100% with 0.1?mg/kg;% of responders who relapsed by day 14: 30% with 1.0?mg/kg, 50% with 0.5?mg/kg, 80% with 0.1?mg/kg).The sample size was small. No MADRS measurements at day one post-infusion. The study was not powered to assess differences in relapse prevention between different doses of ketamine.Time to relapse after successful treatment with a single infusion of ketamine appears to follow a dose-response relationship, where higher dosage leads to increased time to relapse.

View details for DOI 10.1016/j.jad.2019.09.017

View details for PubMedID 31494365